The safety of newly approved medicines: do recent market removals mean there is a problem?
The removal of 5 pharmaceuticals from the market in a 12-month period because of unexpected adverse events raised concerns about the adequacy of the drug review process at the US Food and Drug Administration (FDA). Specifically, concerns were raised about improvements in drug review efficiency that significantly reduced FDA review times. We have reviewed the circumstances of the 5 removals to determine whether there was any relationship to the increased efficiencies in the drug review process. When the removed drugs were analyzed by date of approval, no increase in the number of drugs taken off the market was seen, demonstrating that reduced review processing time was not the reason for the cluster of removals. We conclude that the agency's drug review procedures and postmarketing surveillance system after a drug has been marketed are currently adequate but must continually adjust to future challenges.
D016907:Adverse Drug Reaction Reporting Systems; D018926:Anti-Allergic Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001067:Appetite Depressants; D001562:Benzimidazoles; D001577:Benzophenones; D001969:Bromobenzenes; D002121:Calcium Channel Blockers; D020372:Dexfenfluramine; D017277:Drug Approval; D004335:Drug and Narcotic Control; D005277:Fenfluramine; D011358:Product Surveillance, Postmarketing; D016593:Terfenadine; D013764:Tetrahydronaphthalenes; D014481:United States; D014486:United States Food and Drug Administration